<DOC>
	<DOC>NCT00102479</DOC>
	<brief_summary>The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.</brief_summary>
	<brief_title>Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Children and adolescents between 1017 years, in good physical health, preferentially with a primary schizophrenia spectrum diagnosis or bipolar spectrum disorder History of mental retardation Any neurological disorder with the exception of Pervasive Developmental Disorder (PDD), Attention Deficit Hyperactivity Disorder (ADHD), and Touretteâ€™s Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Pharmacokinetics,</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>acute mania in pediatric populations</keyword>
</DOC>